��«����Ƶ

��«����Ƶ recently announced plans to build a new cardiovascular device manufacturing facility in Georgia, which is expected to be completed in 2028. The announcement follows strong second-quarter performance for our cardiovascular business, with Electrophysiology, Heart Failure and Structural Heart all delivering double-digit organic sales growth. 

The Georgia facility is ��«����Ƶ’s second investment in U.S. manufacturing in 2025. In April, we announced new investments in U.S. manufacturing and R&D that will expand our transfusion diagnostics business, which screens more than 50% of the . Those investments, totaling $500 million, will create 300 new American jobs. 

These developments further ��«����Ƶ's long history of investment in American innovation. Over the last five years, we've invested more than $15 billion in U.S. operations, including manufacturing, equipment and R&D. With world headquarters in north suburban Chicago, 35 manufacturing sites in 15 states and 43 R&D sites in 13 states, ��«����Ƶ has a larger presence in the U.S. than in any other country or region. We’ve also made investments globally, as we operate our manufacturing and supply chain network to be resilient and close to customers we serve.

Entering a $1B Market With Next-Generation Molecular Diagnostics

With our new investments in transfusion diagnostics manufacturing, ��«����Ƶ will enter the molecular nucleic acid blood and plasma testing market, which is estimated to represent an approximately $1 billion market opportunity. To ensure the safety of recipients of blood component transfusions and plasma-derived therapies, donations must be screened for infectious diseases, such as HIV and hepatitis, as well as other pathogens using serology and molecular testing. Our current blood and plasma screening system, Alinity s, runs serology screening tests. Our new Alinity n system will perform molecular testing, capable of detecting DNA and RNA for multiple pathogens. It is a compact instrument intentionally designed with customers in mind. 

"Our transfusion medicine, R&D, medical affairs and marketing teams have visited key organizations around the world to understand their pain points, work to address unmet needs and ensure that this solution would serve the community in the best way," says Elizabeth Balthrop, Vice President, . "We've shared our advancements and our scientific breakthrough with leaders in the industry and the feedback they've provided us has been encouraging as they think about how to manage their blood and plasma supply."